Drug intelligence / Profile preview

FFT-087

Development stage: Preclinical
Lead developer: F5 Therapeutics
Modality: Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous

Overview

FFT-087 is a preclinical-stage drug candidate developed by F5 Therapeutics. It is classified as a degrader-antibody conjugate, a modality that combines targeted protein degradation with antibody-based delivery. The drug is being investigated for therapeutic use in neoplasms (cancers), digestive system disorders, and respiratory diseases. Active indications under research include breast cancer, head and neck neoplasms, and hepatocellular carcinoma. As of the latest update in March 2025, FFT-087 has not yet entered clinical trials beyond the preclinical phase[2].

Beyond the preview

Go deeper on FFT-087.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FFT-087.

Explore the full profile